Overview

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Status:
RECRUITING

Trial end date:
2030-05-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.

Phase:

PHASE3

Details

Lead Sponsor:

Neurocrine Biosciences